Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation
Open Access
- 12 May 2020
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (5), 93
- https://doi.org/10.3390/ph13050093
Abstract
Cytokine-induced killer (CIK) cells are advanced therapy medicinal products, so their production and freezing process has to be validated before their clinical use, to verify their stability as a drug formulation according to the good manufacturing practice (GMP) guidelines. We designed a stability program for our GMP-manufactured CIK cells, evaluating the viability, identity and potency of cryopreserved CIK cells at varying time periods from freezing, and compared them with fresh CIK cells. We evaluated the effects of the cryopreservation method, transportation, and the length of time of different process phases (pre-freezing, freezing and post-thawing) on the stability of CIK cells. This included a worst case for each stage. The expanded CIK cells were viable for up to 30 min from the addition of the freezing solution, when transported on dry ice within 48 h once frozen, within 60 min from thawing and from 12 months of freezing while preserving their cytotoxic effects. The reference samples, cryopreserved simultaneously in tubes and following the same method, were considered representative of the batch and useful in the case of further analysis. Data obtained from this drug stability program can inform the accurate use of CIK cells in clinical settings.This publication has 19 references indexed in Scilit:
- The Utilization of Freezing Steps in Mesenchymal Stromal Cell (MSC) Manufacturing: Potential Impact on Quality and Cell Functionality AttributesFrontiers in Immunology, 2019
- Stability enhancement of clinical grade multipotent mesenchymal stromal cell-based productsJournal of Translational Medicine, 2018
- Cytokines induced killer cells produced in good manufacturing practices conditions: identification of the most advantageous and safest expansion method in terms of viability, cellular growth and identityJournal of Translational Medicine, 2018
- Innovative Clinical Perspectives for CIK Cells in Cancer PatientsInternational Journal of Molecular Sciences, 2018
- Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical applicationHuman Vaccines & Immunotherapeutics, 2017
- Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC)Zeitschrift für Krebsforschung und Klinische Onkologie, 2014
- Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC)Zeitschrift für Krebsforschung und Klinische Onkologie, 2010
- Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I studyHaematologica, 2007
- Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantationBone Marrow Transplantation, 2006
- Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.The Journal of Experimental Medicine, 1991